Antibodies and Vaccines Target RBD of SARS-CoV-2
The novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which gives rise to the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. On March 11, 2020, the WHO had officially announced COVID-19 as a pandemic. Therefore, it is vi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2021.671633/full |
| _version_ | 1818457947206844416 |
|---|---|
| author | Long Min Qiu Sun |
| author_facet | Long Min Qiu Sun |
| author_sort | Long Min |
| collection | DOAJ |
| description | The novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which gives rise to the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. On March 11, 2020, the WHO had officially announced COVID-19 as a pandemic. Therefore, it is vital to find effective and safe neutralizing antibodies and vaccines for COVID-19. The critical neutralizing domain (CND) that is contained in the receptor-binding domain (RBD) of the spike protein (S protein) could lead to a highly potent neutralizing antibody response as well as the cross-protection of other strains of SARS. By using RBD as an antigen, many neutralizing antibodies are isolated that are essential to the therapeutics of COVID-19. Furthermore, a subunit vaccine, which is based on the RBD, is expected to be safer than others, thus the RBD in the S protein is a more important target for vaccine development. In this review, we focus on neutralizing antibodies that are targeting RBD as well as the vaccine based on RBD under current development. |
| first_indexed | 2024-12-14T22:50:39Z |
| format | Article |
| id | doaj.art-f9bffa9accc049369df7795717a66c39 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-12-14T22:50:39Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-f9bffa9accc049369df7795717a66c392022-12-21T22:44:45ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2021-04-01810.3389/fmolb.2021.671633671633Antibodies and Vaccines Target RBD of SARS-CoV-2Long MinQiu SunThe novel human coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which gives rise to the coronavirus disease 2019 (COVID-19), has caused a serious threat to global public health. On March 11, 2020, the WHO had officially announced COVID-19 as a pandemic. Therefore, it is vital to find effective and safe neutralizing antibodies and vaccines for COVID-19. The critical neutralizing domain (CND) that is contained in the receptor-binding domain (RBD) of the spike protein (S protein) could lead to a highly potent neutralizing antibody response as well as the cross-protection of other strains of SARS. By using RBD as an antigen, many neutralizing antibodies are isolated that are essential to the therapeutics of COVID-19. Furthermore, a subunit vaccine, which is based on the RBD, is expected to be safer than others, thus the RBD in the S protein is a more important target for vaccine development. In this review, we focus on neutralizing antibodies that are targeting RBD as well as the vaccine based on RBD under current development.https://www.frontiersin.org/articles/10.3389/fmolb.2021.671633/fullSARS-CoV-2RBDantibodiesvaccinesCOVID-19 |
| spellingShingle | Long Min Qiu Sun Antibodies and Vaccines Target RBD of SARS-CoV-2 Frontiers in Molecular Biosciences SARS-CoV-2 RBD antibodies vaccines COVID-19 |
| title | Antibodies and Vaccines Target RBD of SARS-CoV-2 |
| title_full | Antibodies and Vaccines Target RBD of SARS-CoV-2 |
| title_fullStr | Antibodies and Vaccines Target RBD of SARS-CoV-2 |
| title_full_unstemmed | Antibodies and Vaccines Target RBD of SARS-CoV-2 |
| title_short | Antibodies and Vaccines Target RBD of SARS-CoV-2 |
| title_sort | antibodies and vaccines target rbd of sars cov 2 |
| topic | SARS-CoV-2 RBD antibodies vaccines COVID-19 |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2021.671633/full |
| work_keys_str_mv | AT longmin antibodiesandvaccinestargetrbdofsarscov2 AT qiusun antibodiesandvaccinestargetrbdofsarscov2 |